Inhibikase Therapeutics (IKT) Stock Price Target 2026

The average analyst price target for Inhibikase Therapeutics is $4.94, 240.7% above the current price. Of 8 analysts, 7 rate it Buy and 1 Hold. Targets range from $1.50 to $8. The latest change came on Oct 13, 2026, when Chardan Capital initiated coverage of Inhibikase Therapeutics with a Neutral rating and a $1.50 price target.